Status:
COMPLETED
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
Lead Sponsor:
Laval University
Conditions:
Overweight
Microbiota
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
It has been suggested that the actual obesity epidemy is related to chronic overconsumption of added or free sugars. The increasing popularity of artificial sweeteners attest the population willingnes...
Eligibility Criteria
Inclusion
- BMI between 23 and 40 kg/m2
- At least one of the following: Fasting triglyceride \> 1,35 mmol/L, Fasting insulinemia \> 42 pmol/L, fasting glycemia between 5,5 and 6,9 mmol/L and glycated haemoglobin (HbA1c) between 5.7 and 6.4 %
- Understanding of spoken and written french
- Accept to follow study instructions
- If there is natural health product consumption, the dose and frequency of consumption must be stable since 3 months or more
Exclusion
- Smoking
- Any metabolic disorder requiring medication or affecting glucose or lipid metabolism
- Aversion for maple taste
- Allergy or intolerance for maple syrup or for an ingredient of the placebo syrup
- Alcohol consumption of \> 2 drinks / day
- Weight change \> 5% of body weight in the last 3 months
- Being in a weight loss attempt
- Antibiotics intake in the last 3 months
- Regular probiotics intake in the last 3 months
- Major surgical operation in the last 3 months or planned in the next months
- Gastrointestinal malabsorption
- Cirrhosis
- Chronic kidney disease
- Pregnant or breastfeeding women or women planning pregnancy in the next months
- Participation in another clinical trial
Key Trial Info
Start Date :
September 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04117802
Start Date
September 3 2019
End Date
December 1 2021
Last Update
April 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
INAF, Université Laval
Québec, Canada, G1V 0A6